Neuland Laboratories posts blockbuster FY26 performance

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Plus Therapeutics subsidiary clears key Medicare milestone

Paves way for CNS cancer test rollout

Bristol Myers Squibb wins EU nod for Sotyktu in active psoriatic arthritis

The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio

Miror Therapeutics partners with BESCOM to drive menopause awareness among women employees

In collaboration with the Soham Foundation, the initiative focused on perimenopause, menopause, and hormone replacement therapy awareness at BESCOM’s Bengaluru headquarters.

MilliporeSigma lands exclusive 5-year deal to test Genetix Biotherapeutics gene therapies

The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy

Neurobion introduces nerve pain relief cream

The formulation contains 0.075% Capsaicin, a clinically proven ingredient along with menthol, camphor and eucalyptus oil

GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD

This is an exciting and meaningful milestone for GRIN Therapeutics

Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform

LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy